EDITORIAL SECTION

Articles

Radical Optionality to Leadership Reinvention: Dual Framework for Biotech-CDMO Transformation

Biotech and CDMOs stand at a pivotal crossroads On one side scientific complexity is acceleratingnew modalities such as antibodydrug conjugates mRNA oligonucleotides and cell and gene therapies demand faster more adaptive development models On the other side systemic pressures are tighteningthe biotech funding squeeze the Biosecure Act and fractured global supply chains are forcing organisations t...

Adaptive Trial Designs: Enhancing Speed and Decision-Making in Clinical Development

For decades the traditional clinical trial has followed a rigid script A protocol is written patients are enrolled the study runs to completion and only at the very end does the sponsor learn whether the investment paid off The model has served the industry well in terms of scientific rigour

Digital Twins in Pharmaceutical R&D: Simulating Biology for Faster Innovation

For most of its modern history pharmaceutical research has been an experimental science with a statistical conscience Build the molecule dose the animal run the trial count the failures and let the survivors pay for everything that did not make it That arrangement has become progressively harder to defend Attrition remains concentrated in the phases where money has already

The Cost of Uncertainty: How Analytical Chemistry Drives Billion-Dollar Decisions in Pharma

In pharmaceutical development uncertainty is not an abstract scientific inconvenience It has a cost a timeline a regulatory consequence and ultimately a patient impact A promising medicine may have strong biological rationale compelling early data and significant commercial potential yet still face a fundamental question do we truly understand the product well enough to develop manufacture approve...

How AI Could Improve R&D Productivity Across the European Pharma Sector

Few industries invest in the future as heavily as European pharma According to the regions pharmaceutical industry federation the sector invested an estimated billion in research and development in Europe in making it the most researchintensive industry on the continent Yet boards increasingly confront an uncomfortable asymmetry Spending keeps climbing while the outputs that matter most

Adapting to the Post-Brexit Pharma Environment: Strategies for Success

The pharmaceutical industry has undergone significant changes following the United Kingdoms departure from the European Union commonly known as Brexit This historic event has introduced new challenges and opportunities for pharmaceutical

Techno Trends

Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein

Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue

Projects

SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing

SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more

Research Insights

A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG

PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine

whitepaper

Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact

For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys